Evidence map›Paper›PMID 41201017›Full record

ReviewOncology reports2026

Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).

Guangyao Li, Binghui Jin, Jialin Zhou, Shifeng Fang, Zhe Fan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guangyao Li *Department of Oncology, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning 110000, P.R. China.
Binghui Jin *Department of General Surgery, The Third People's Hospital of Dalian, Dalian Medical University, Dalian, Liaoning 116000, P.R. China.
Jialin Zhou *Department of General Surgery, The Third People's Hospital of Dalian, Dalian Medical University, Dalian, Liaoning 116000, P.R. China.
Shifeng FangDepartment of Ophthalmology, Liaoning Provincial Key Laboratory of Cornea and Ocular Surface Diseases, Liaoning Provincial Optometry Technology Engineering Research Center, Dalian Third People's Hospital Affiliated to Dalian University of Technology, Dalian, Liaoning 116000, P.R. China.
Zhe FanDepartment of General Surgery, The Third People's Hospital of Dalian, Dalian Medical University, Dalian, Liaoning 116000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) ranks among the most prevalent malignant tumors in female patients. It represents a longstanding challenge to medical professionals in terms of diagnosis and treatment. Exploring BC pathogenesis offers insight into its complexity and facilitates the exploration of more effective treatment strategies. The present review aimed to describe the involvement of the immune system, inflammatory response and regulated cell death in BC development, offering avenues for novel therapeutic strategies against BC. Identifying novel treatment methods is key for enhancing the prognosis of patients with BC.

Indexed as

Breast NeoplasmsImmune SystemInflammationRegulated Cell DeathFemaleHumansPrognosisTumor Microenvironmentbreast cancerimmune systeminflammatory responseregulated cell deaththerapy

Identifiers

PMID41201017
PMCPMC12612799

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.